This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Discussing Welireg (Belzutifan) as a treatment in patients with von Hippel-Lindau (VHL) disease with associated renal cell carcinoma

Ticker(s): MRK

Who's the expert?

Institution: Huntsman Cancer Institute, University of Utah

  • Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies
  • Participated in two clinical trials with Welireg and is now using it as standard of care
  • Clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers.

Interview Questions

Please describe your clinical practice. Roughly how many patients with VHL do you currently manage?

Added By: sara_admin

What are your thoughts on the use of Welireg and how does it compare to other treatment options?

Added By: sara_admin

On a scale from 1-10 (10 being extremely excited), how would you rate your level of excitement for Welireg?

Added By: sara_admin

Can you discuss the role of HIF2 alpha in oncogenesis and which tumors in particular this plays a significant role?

Added By: sara_admin

Who are the specific types of patients you are treating so far with Welireg?

Added By: sara_admin

Potential for off label usage in sporadic advanced RCC?

Added By: sara_admin

What is Welireg's potential in more broad application beyond VHL for RCC or other tumor types?

Added By: sara_admin

Can you discuss the unmet need in RCC?

Added By: sara_admin

Did you consider the trial data for label indication compelling?

Added By: sara_admin

Can you address the toxicity profile and whether you think it has potential in combinations?

Added By: sara_admin

Related to the checkpoint inhibitor combination, what are your thoughts on HIF mechanism and how it impacts immune cell populations?

Added By: sara_admin

What are your Clinical observations post-approval? Are you seeing responses? Any responses in advanced RCC off label usage?

Added By: sara_admin

What is your view of Welireg's future/potential in RCC - 2nd line immunotherapy potential? Combos?

Added By: sara_admin

How has the process been for getting patients approved for access to Welireg?

Added By: sara_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.